|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Trial** | **Sample size(M)** | **Age(y)±SD** | **Dose(mg/d)** | **Country** | **follow-up** | **Stent** | **Duration\*** |
|  |  | **P** | **C** |  |  |  |  |  |
| **Setsuda 199316** | 67(51) | 58.8±8 | 61±7.9 | 750/1000 | Japan | 3-6 m | No | >7 days |
| **Watanabe 199617** | 118(91) | 62.7±10.1 | 64.1±11.7 | 500 | Japan | 3-6 m | No | 7 days |
| **Tardif 199718** | 159(126) | 58.5±9.3 | 60.3±8.4 | 500 | Canada | 5-7 m | N0 | 30 days |
| **Yokoi 199719** | 78(64) | 60±9 | 60±9 | 1000 | Japan | 24 w | N0 | 4 weeks |
| **Sekiya 199820** | 63(44) | 64±11 | 65±10 | 500 | Japan | 6 m | Yes | 5 days |
| **Kim 200221** | 70(49) | 57.83±7.51 | 55.8±7.89 | 500 | Korea | 6 m | Yes | 3 days |
| **Tardif 200322** | 121(97) | 61.1±10.9 | 58.2±10.1 | 1000 | Canada | 5-7 m | Yes | 14 days |
| **Wakeyama 200323** | 89(66) | 65±8 | 67±9 | 1000 | Japan | 6 m | Yes | No |
| **Kaminnyi 200524** | 40(40) | 55.0±5.4 | 55.0±5.4 | 250 | Russia | 6 m | No | 7-10 days |
| **Nunes 200625** | 54(34) | 59.1±9.1 | 60.1±9.7 | 1000 | Brazil | 6 m | Yes | 14 days |

**Table 1: Study characteristics**

**Note:** M, men; P, probucol group (standard drug treatment plus only probucol); C, control group (usual drug treatment without any lipid-lowering drugs); Duration\*: duration of drug-use before PCI